AlbionVC
No summary available yet.
AlbionVC is the grown-up in the room of UK venture - they've been doing this since 1996 and it shows in their disciplined, thesis-driven approach. Their partners project an aura of patience and take a genuinely long-term view, with reputation and consistency carrying more weight than flashy deals. Founders consistently praise Ed Lascelles specifically - Tony Pepper from Egress called him "equally important" to their success alongside the team and tech, while Quantexa's CEO said they've been privileged to work with Ed and AlbionVC from the beginning. They actually stick around - Quantexa went from first investment in 2017 to a $175m Series F at $2.6bn valuation in 2025, with AlbionVC participating in every round. The downside? They're not going to move fast on trendy deals, and if you want VC theater or ego stroking, look elsewhere.
- —Best for: UK B2B software/healthcare founders wanting patient, long-term capital partners
- —Known for: Sticking with companies through multiple rounds and genuine post-investment support
- —Watch out for: Slower decision-making and very thesis-focused investment criteria
AlbionVC's investment thesis centers on building category leaders in software, fintech, and healthcare through capital-efficient scaling, targeting companies with clear product-market fit, strong recurring revenue, and large addressable markets. They follow a thesis-driven approach across three core domains: software, healthcare, and deeptech, sticking to areas where their team has built deep domain expertise rather than chasing hot trends.
They invest from seed through to Series B in high growth companies, predominantly in the UK, with a focus on B2B software and technology enabled services. Real portfolio evidence shows 35 investments in Series A (average $11.2M), 28 in Seed (average $5.47M), 9 in Series B (average $26.3M), and 2 in Series C (average $62.4M). Recent activity focuses on deeptech, healthcare, and B2B software companies, building on portfolio successes like Quantexa, Oviva, and tem.
Ed has been with Albion since 2004 and heads up their tech team, discovering startups in B2B software, fintech, cyber, AI and deeptech. He graduated from UCL with a degree in philosophy and worked in banking with ING Barings & Charterhouse before joining Albion. He was the first investor in cybersecurity leader Egress (acquired by KnowB4) and an early investor in fintech Credit Kudos (acquired by Apple), plus blockchain analytics firm Elliptic and decision intelligence platform Quantexa.
Andrew joined Albion in 2005 and focuses on medical technologies, digital health and technology-enabled services to the life-science sector. He initially practiced as a surgeon for six years before joining Boston Consulting Group in 2001 specializing in healthcare strategy, and has an MA plus Bachelors of Medicine and Surgery from Cambridge University. He also oversees management of the UCL Technology Fund and has invested in sectors ranging from digital health, diagnostics and imaging, machine learning applications and therapeutics, including cell and gene therapies.
Cat joined Albion in 2018 and focuses on fintech, security and productivity, particularly interested in software transforming big, legacy industries as well as tech solving core issues for society. Prior to joining Albion, Cat worked in New York and London as an Investment Banker with Goldman Sachs and holds a degree in Economics from Harvard University. She was promoted to Partner in 2024 alongside three others, reflecting her extensive experience and consistently strong performance.
Have a specific question about AlbionVC?
Ask Bernie →